Catalysts for RBC Capital's 2015 Top Small Cap Biotech Picks

Each year analysts pick their favorite biotechs and identify which they feel have the most upside. RBC Capital picked 5 small cap biotechs for 2015. Here are the catalyst events to watch for. 1. Xenoport

The company is expecting to report topline data from a Phase 2 trial in moderate-to-severe plaque psoriasis in the third quarter. RBC also sites better than expected Horizant sales as a potential value driver. RBC rated Xenoport an Outperform and set a $10 price target. 2. Dyax Corp

Dyax is expecting to release topline results from a Phase 1b trial of DX-2930 for Hereditary Angioedema in the first quarter. Dyax's partner Biogen is also expected to release top-line Phase 2 data of anti-LINGO trial for acute optic neuritis in early 2015. Dyax's partnership includes a 2.5% royalty rate. RBC rated Dyax an Outperform and set an $18 price target. 3. The Medicines Company

The Medicines Company has a PDUFA date of January 31 for Raplixa used to aid in hemostasis during surgery. They also expect to receive approval for Ionsys sometime in 2015. RBC rated Medicines Company an Outperform and set a $38 price target. 4. Aerie Pharmaceuticals

Aerie is expected to release Phase 3 data of Rhopressa for glaucoma from the Rocket 1 trial in the middle of the second quarter. The company will also release data from the Rocket 2 trial in the middle of 2015. RBC rated Aerie a Speculative Risk Outperform and set a $45 price target.